180 related articles for article (PubMed ID: 35689262)
61. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
62. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
63. Combined legumain- and integrin-targeted nanobubbles for molecular ultrasound imaging of breast cancer.
Mi X; Guo X; Du H; Han M; Liu H; Luo Y; Wang D; Xiang R; Yue S; Zhang Y; Tan X
Nanomedicine; 2022 Jun; 42():102533. PubMed ID: 35150904
[TBL] [Abstract][Full Text] [Related]
64. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
65. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
66. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents.
Gao Y; Hernandez C; Yuan HX; Lilly J; Kota P; Zhou H; Wu H; Exner AA
Nanomedicine; 2017 Oct; 13(7):2159-2168. PubMed ID: 28603079
[TBL] [Abstract][Full Text] [Related]
67. Nanobubble-Affibody: Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor.
Yang H; Cai W; Xu L; Lv X; Qiao Y; Li P; Wu H; Yang Y; Zhang L; Duan Y
Biomaterials; 2015 Jan; 37():279-88. PubMed ID: 25453958
[TBL] [Abstract][Full Text] [Related]
68. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
[TBL] [Abstract][Full Text] [Related]
69. Optical Imaging of Triple-Negative Breast Cancer Cells in Xenograft Athymic Mice Using an ICAM-1-Targeting Small-Molecule Probe.
Zhang Y; Wang M; Liu W; Peng X
Mol Imaging Biol; 2019 Oct; 21(5):835-841. PubMed ID: 30623283
[TBL] [Abstract][Full Text] [Related]
70. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
71. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
72. ZD2-Engineered Gold Nanostar@Metal-Organic Framework Nanoprobes for T
Zhang L; Liu C; Gao Y; Li Z; Xing J; Ren W; Zhang L; Li A; Lu G; Wu A; Zeng L
Adv Healthc Mater; 2018 Dec; 7(24):e1801144. PubMed ID: 30370656
[TBL] [Abstract][Full Text] [Related]
73. The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with
Bouchard A; Sikner H; Baverel V; Garnier AR; Monterrat M; Moreau M; Limagne E; Garrido C; Kohli E; Collin B; Bellaye PS
Cells; 2021 Dec; 10(12):. PubMed ID: 34943901
[TBL] [Abstract][Full Text] [Related]
74. Nanobubbles as ultrasound contrast agent for facilitating small cell lung cancer imaging.
Wang JP; Zhou XL; Yan JP; Zheng RQ; Wang W
Oncotarget; 2017 Sep; 8(44):78153-78162. PubMed ID: 29100457
[TBL] [Abstract][Full Text] [Related]
75. Inhibition of Mitochondrial Biosynthesis Using a "Right-Side-Out" Membrane-Camouflaged Micelle to Facilitate the Therapeutic Effects of Shikonin on Triple-Negative Breast Cancer.
Peng J; Hu X; Fan S; Zhou J; Ren S; Sun R; Chen Y; Shen X; Chen Y
Adv Healthc Mater; 2022 Sep; 11(18):e2200742. PubMed ID: 35818932
[TBL] [Abstract][Full Text] [Related]
76. Herceptin-decorated paclitaxel-loaded poly(lactide-
Zhong S; Ling Z; Zhou Z; He J; Ran H; Wang Z; Zhang Q; Song W; Zhang Y; Luo J
Pharm Dev Technol; 2020 Apr; 25(4):454-463. PubMed ID: 31873051
[TBL] [Abstract][Full Text] [Related]
77. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
78. Nano-delivery of
Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
[TBL] [Abstract][Full Text] [Related]
79. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
80. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
